Salazopyrin in rheumatoid arthritis
- 1 June 1978
- journal article
- research article
- Published by Springer Nature in Inflammation Research
- Vol. 8 (4) , 438-441
- https://doi.org/10.1007/bf01968673
Abstract
After a 12-week preliminary period of observation 32 patients with consistently active rheumatoid arthritis (RA) were treated for up to 22 weeks with salazopyrin. Seven patients could not tolerate the drug. The remaining 25 patients had a marked improvement in subjective clinical state and significant falls in serum C-reactive protein and the erythrocyte sedimentation rate 6 weeks after treatment began. The improvement was maintained after 22 weeks. The results strongly suggest that further trials with this drug in RA are needed.This publication has 17 references indexed in Scilit:
- Rheumatoid arthritis: C-reactive protein and erythrocyte sedimentation rate during initial treatment.BMJ, 1978
- Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis.BMJ, 1977
- Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes.BMJ, 1977
- MULTIPLE IMMUNE COMPLEXES AND HYPOCOMPLEMENTÆMIA IN DERMATITIS HERPETIFORMIS AND CŒLIAC DISEASEThe Lancet, 1976
- DAPSONE IN RHEUMATOID ARTHRITISRheumatology, 1976
- Pathology, pathogenesis, and aetiology of rheumatoid arthritis.Annals of the Rheumatic Diseases, 1972
- CONTROLLED TRIAL OF SULPHASALAZINE IN MAINTENANCE THERAPY FOR ULCERATIVE COLITISThe Lancet, 1965
- Sulfapyridine and Sulfone Type Drugs in DermatologyArchives of Dermatology, 1962
- Treatment of Rheumatoid Arthritis with salicylazosulfapyridineActa Medica Scandinavica, 1958
- Salazopyrin, a new sulfanilamide preparation. A. Therapeutic Results in Rheumatic Polyarthritis. B. Therapeutic Results in Ulcerative Colitis. C. Toxic Manifestations in Treatment with Sulfanilamide Preparations.Acta Medica Scandinavica, 1942